All In Biotech

Drug Trial Radar · NCT05073003

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

A Staged Phase I/II Observer-blind, Randomised, Controlled, Multi-country Study to Evaluate the Safety, Reactogenicity, and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against S. Sonnei and S. Flexneri, Serotypes 1b, 2a, and 3a, in Adults in Europe (Stage 1) Followed by Age De-escalation From Adults to Children and Infants, and Dose-finding in Infants in Africa (Stage 2)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 551 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

551

Actual

Start

Oct 6, 2021

Primary completion

Jun 24, 2025

Study completion Jun 24, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 9 months, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine was first administered to adults 18 to 50 years of age in Europe. Subsequently, the vaccine was administered to a shigellosis-endemic population in Africa, first to adults 18 to 50 years of age, then to children 24 to 59 months of age, and finally to infants 9 months of age. Infants also received a third vaccination. Three different doses of the vaccine \[low, medium, and high amounts of antigen\] were evaluated using an age de-escalation approach (from the least vulnerable adult population to the most vulnerable paediatric population). The results of this study allowed the selection of the most appropriate dose for further vaccine development in infants 9 months of age, which was the main target age group for this vaccine.

Conditions

  • Diarrhoea

Interventions

  • AltSonflex1-2-3 High DoseBiological

    2 doses in adults 18-50 years of age and children 24-59 months of age, 3 doses in infants 9 months of age

  • AltSonflex1-2-3 Medium DoseBiological

    2 doses in children 24-59 months of age, 3 doses in infants 9 months of age

  • AltSonflex1-2-3 Low DoseBiological

    3 doses in infants 9 months of age

  • MenveoBiological

    1 dose in adults 18-50 years of age (stage 2) and children 24-59 months of age and 2 doses in infants 9 months of age

  • BoostrixCombination product

    1 dose in adults 18-50 years of age (stage 2)

  • INFANRIX HEXACombination product

    1 dose in infants 9 months of age

  • Typhim-ViCombination product

    1 dose in children 24-59 months of age

  • MR-VacBiological

    2 doses in children 24-59 months of age

  • altSonflex PlaceboDrug

    2 doses in adults 18-50 years of age (stage 1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 2: Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG) in Participants 9 Months of Age in AfricaTime frame: At Day 281 (28 days after the third study intervention)
  2. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Solicited Administration Site EventsTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
  3. Stage 1: Number of Adults 18 to 50 Years of Age in Europe With Solicited Systemic EventsTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
  4. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Unsolicited Adverse Events (AEs)Time frame: Within 28 days after each study intervention (administered at at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
  5. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 113 and/or Day 197
  6. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study InterventionTime frame: At Day 8
  7. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study InterventionTime frame: At Day 92 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 1), at Day 176 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 2) and at Day 92/Day 176 (Stage 1 Adults: Placebo Group)
  8. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Administration Site EventsTime frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
  9. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Systemic EventsTime frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
  10. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Unsolicited Adverse Events (AEs)Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)
  11. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 113
  12. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study InterventionTime frame: At Day 8
  13. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study InterventionTime frame: At Day 92
  14. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Administration Site EventsTime frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
  15. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Systemic EventsTime frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
  16. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Unsolicited Adverse Events (AEs)Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)
  17. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 113
  18. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study InterventionTime frame: At Day 8
  19. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study InterventionTime frame: At Day 92
  20. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Safety CohortTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  21. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Dose-finding CohortTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  22. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Safety CohortTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  23. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Dose-finding CohortTime frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  24. Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Safety CohortTime frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  25. Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Dose-finding CohortTime frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
  26. Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety CohortTime frame: From Day 1 to Day 281
  27. Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding CohortTime frame: From Day 1 to Day 281
  28. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Safety CohortTime frame: At Day 8
  29. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Dose-finding CohortTime frame: At Day 8
  30. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Safety CohortTime frame: At Day 92
  31. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Dose-finding CohortTime frame: At Day 92
  32. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Safety CohortTime frame: At Day 260
  33. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Dose-finding CohortTime frame: At Day 260

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Kericho, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.